Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials

International Immuno-Oncology Biomarker Working Group

Producción científica: Contribución a una revistaArtículo de revisiónrevisión exhaustiva

15 Citas (Scopus)

Resumen

Stromal tumor-infiltrating lymphocytes (sTILs) are a potential predictive biomarker for immunotherapy response in metastatic triple-negative breast cancer (TNBC). To incorporate sTILs into clinical trials and diagnostics, reliable assessment is essential. In this review, we propose a new concept, namely the implementation of a risk-management framework that enables the use of sTILs as a stratification factor in clinical trials. We present the design of a biomarker risk-mitigation workflow that can be applied to any biomarker incorporation in clinical trials. We demonstrate the implementation of this concept using sTILs as an integral biomarker in a single-center phase II immunotherapy trial for metastatic TNBC (TONIC trial, NCT02499367), using this workflow to mitigate risks of suboptimal inclusion of sTILs in this specific trial. In this review, we demonstrate that a web-based scoring platform can mitigate potential risk factors when including sTILs in clinical trials, and we argue that this framework can be applied for any future biomarker-driven clinical trial setting.

Idioma originalInglés
Número de artículo15
Publicaciónnpj Breast Cancer
Volumen6
N.º1
DOI
EstadoPublicada - 1 dic. 2020

Nota bibliográfica

Publisher Copyright:
© 2020, The Author(s).

Huella

Profundice en los temas de investigación de 'Application of a risk-management framework for integration of stromal tumor-infiltrating lymphocytes in clinical trials'. En conjunto forman una huella única.

Citar esto